Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in previously treated patients with non-small cell lung cancer with non-classical and C797S EGFR mutations.Helena A. Yu, Melissa L. Johnson, Danny Nguyen et al.|Journal of Clinical Oncology|2026Cited by 1
Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.Atulya Aman Khosla, M. Ahluwalia, Parth Dhamelia et al.|Journal of Clinical Oncology|2026Cited by 0
Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.Atulya Aman Khosla, M. Ahluwalia, Parth Dhamelia et al.|Journal of Clinical Oncology|2026Cited by 0